05 November 2004
Munich, Germany; Illkirch, France - Neuronova AG, a biopharmaceutical company developing novel drugs against depression, and Prestwick Chemical Inc., an expert in medicinal chemistry, have entered into a collaboration by which Prestwick Chemical will apply its integrated medicinal chemistry platform to optimise a small molecule compound with antidepressant properties identified by Neuronova.
The compound interacts with a novel target proprietary to Neuronova which is involved in the development of depression and bipolar affective disorders. Resulting drugs are expected to act faster and address larger patient segments than current antidepressants.
Prof. Camille Wermuth, President and Chief Scientific Officer of Prestwick Chemical Inc. said: “The goal of our collaboration is to transform the original hit found by the scientists of Neuronova into a valuable clinical candidate. Following a structure activity study, we will focus on increasing its potency, selectivity, and its oral bioavailability.”
Dr. Herbert Stadler, Chief Executive Officer of Neuronova AG, commented: "The chemistry expertise provided by Prestwick Chemical ideally complements our in-house behavioural pharmacology program and the collaboration will accelerate the development of Neuronova's programs into clinical development".
Contact for Neuronova AG:
Dr. Herbert Stadler
Chief Executive Officer
Kraepelinstraße 2
Tel.: +49 (0)89 30622-591
Fax: +49 (0)89 30622-370
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Contact for Prestwick Chemical Inc.:
Prof. Camille G. Wermuth
President & Chief Scientific Officer
Bd Gonthier d’Andernach
F-67400 Illkirch
Tel.: +33 (0)369 20 16 00
Fax: +33 (0)369 20 16 17
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
| File | File size |
|---|---|
 2004-11 Neuronova Prestwick engl.pdf | 40 Kb |
Copyright © 2012 Affectis Pharmaceuticals AG. All Rights Reserved.
